­
­
­
­

Inventi Impact: Pharmaceutical Process Development

Articles

  • Inventi:ppd/30752/19
    A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects
    Research 2020 : January - March
    Katharina Knaub, Tina Sartorius, Tanita Dharsono, Roland Wacker, Manfred Wilhelm, Christiane Schon

    Cannabidiol (CBD), a phytocannabinoid compound of Cannabis sativa, shows limited oral\nbioavailability due to its lipophilicity and extensive first-pass metabolism. CBD is also known for\nits high intra- and inter-subject absorption variability in humans. To overcome these limitations a\nnovel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology\nincorporating CBD, as Hemp-Extract, was developed (SEDDS-CBD). The study objective was to\nevaluate the pharmacokinetic profile of SEDDS-CBD in a randomized, double-blind, cross-over design\nin 16 healthy volunteers under fasted conditions. As reference formulation, the same Hemp-Extract\ndiluted with medium-chain triglycerides (MCT-CBD) was used. CBD dose was standardized to\n25 mg. Pharmacokinetic parameters were analyzed from individual concentration-time curves���..

    How to Cite this Article
    Attribution/ CC Compliant Citation: Knaub, Katharina, et al. \"A Novel Self-Emulsifying Drug Delivery System (SEDDS)\nBased on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects.\"\nMolecules 24.16 (2019): 2967.\nhttps://doi:10.3390/molecules24162967\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.\n
    Download Full Text